**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 91825

**Manuscript Type:** EDITORIAL

**Disease clearance in ulcerative colitis: A new therapeutic target for the future**

Hassan SA *et al*. Disease clearance in UC

Syed Adeel Hassan, Neeraj Kapur, Fahad Sheikh, Anam Fahad, Somia Jamal

**Syed Adeel Hassan, Neeraj Kapur,** Division of Digestive Disease and Nutrition, University of Kentucky, Lexington, KY 40536, United States

**Fahad Sheikh,** Department of Pathology and Laboratory Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, New York, NY 10461, United States

**Anam Fahad,** Division of Primary Care, Essen Healthcare, New York, NY 10457, United States

**Somia Jamal,** Department of Internal Medicine, Karachi Medical and Dental College, Karachi 74700, Sindh, Pakistan

**Author contributions:** Hassan SA, Kapur N designed the overall content of the study; Hassan SA, Kapur N, Sheikh F, and Fahad A contributed to the writing of the manuscript; Sheikh F and Fahad A contributed to the literature review; Jamal S contributed to the generation of manuscript figure and literature review. All authors have read and approved the final manuscript.

**Corresponding author: Syed Adeel Hassan, MBBS, MD, Research Scientist,** Division of Digestive Disease and Nutrition, University of Kentucky, 800 Rose Street, Lexington, KY 40536, United States. doc.syed92@gmail.com

**Received:** January 6, 2024

**Revised:** February 16, 2024

**Accepted:** March 19, 2024

**Published online:**

**Abstract**

Advancements in murine modeling systems for ulcerative colitis have diversified our understanding of the pathophysiological factors involved in disease onset and progression. This has fueled the identification of molecular targets, resulting in a rapidly expanding therapeutic armamentarium. Subsequently, management strategies have evolved from symptomatic resolution to well-defined objective endpoints, including clinical remission, endoscopic remission and mucosal healing. While the incorporation of these assessment modalities has permitted targeted intervention in the context of a natural disease history and the prevention of complications, studies have consistently depicted discrepancies associated with ascertaining disease status through clinical and endoscopic measures. Current recommendations lack consideration of histological healing. The simultaneous achievement of clinical, endoscopic, and histologic remission has not been fully investigated. This has laid the groundwork for a novel therapeutic outcome termed disease clearance (DC). This article summarizes the concept of DC and its current evidence.

**Key Words:** Inflammatory bowel disease; Ulcerative colitis; Clinical remission; Endoscopic remission; Histological remission; Mucosal healing; Disease clearance

Hassan SA, Kapur N, Sheikh F, Fahad A, Jamal S. Disease clearance in ulcerative colitis: A new therapeutic target for the future. *World J Gastroenterol* 2024; In press

**Core Tip:** Clinical management of ulcerative colitis is guided by a combination of clinical and endoscopic measures, but histologic healing is undervalued. The current definition of disease remission is insufficient due to discrepancies in outcomes. Disease clearance (DC) is a novel emerging composite outcome defined as the simultaneous attainment of clinical, endoscopic and histologic remission. The risk of disease relapse, hospitalization and surgery is significantly lower in patients who achieve DC. It provides superior optimal disease control in the short term. Large prospective studies are needed to determine the cost effectiveness, risk-benefit ratio and impact on long-term outcomes.

**INTRODUCTION**

First described by Samuel Wilks in 1859, ulcerative colitis (UC) is a chronic, idiopathic relapsing inflammatory bowel disease (IBD) limited to the large intestine[1]. UC is characterized by chronic inflammation in the rectum and can progress continuously to the proximal colon[2,3]. The underlying etiology of this disease is considered multifactorial, with increasing focus on aberrant immune response, gut dysbiosis, a compromised gut epithelial barrier, genetic susceptibility and environmental factors[4]. Clinically, patients present with bloody diarrhea, urgency, abdominal pain and tenesmus[2]. Recent studies depict an increasing prevalence of UC, with an estimated 5 million cases globally[5]. In the United States, the epidemiological burden of UC is comparable with global trends, with an incidence and prevalence of 6.3 per 100000 and 378 per 100000 people, respectively[6]. Underlying long-term inflammation alters colonic anatomy and functionality, thus predisposing patients to several downstream sequalae. This subsequently impairs quality of life and increases the risk of disability and colorectal cancer (CRC)[7]. In addition to the significantly increasing disease burden, the progressive and debilitating nature of UC results in a significant economic burden owing to increased direct and indirect costs associated with health care utilization[8]. Pharmacoeconomic data from the Crohn’s and Colitis Foundation of America estimated that the annual economic costs are between US$14.6 and US$31.6 billion[9].

In contrast to its counterpart Crohn’s disease, UC has not been considered a progressive disease[10]. This perception has been rightly altered with the availability of evidence that suggests otherwise[10]. Proximal disease progression is observed in approximately 50% of patients with limited UC at diagnosis[10]. The risk of progression increases with disease duration, notably at 15%, 30% and 50% at 5 years, 10 years and 25 years, respectively[10-12]. An aggressive disease course can lead to colectomy in 10%-15% of patients[12]. Furthermore, disease progression predisposes patients to greater needs for biologics, as well as greater risk for extraintestinal manifestations, pseudopolyposis, anorectal dysfunction, gut dysmotility, surgeries and hospitalizations[13-15].

Due to the availability of only less potent drugs, the natural disease course has not been fully elucidated. Over the past few decades, advancements in murine modeling systems have yielded novel mechanisms of disease onset and progression[16]. This has fueled identification of a wide array of molecular targets, resulting in a rapidly expanding therapeutic armamentarium. The introduction of tumor necrosis factor inhibitors in 2005 set the tone for utilizing advanced therapies in UC[17]. However, their use is complicated by the abundance of serious adverse events, suboptimal response rates and loss of response[18]. Modern biologics and small molecules, such as anti-interleukins, anti-integrins, sphingosine-1-phosphate modulators, and Janus kinase inhibitors (JAKis), provide a cost-effective means of targeting natural disease history[19]. No significant difference in overall safety outcomes was observed between UC patients receiving JAKis and patients receiving other active treatments[20]. Therefore, the safety of JAKis can also be debated. The availability of myriad therapies has shifted therapeutic goals from symptomatic resolution to well-defined objective end points, clinical remission, endoscopic remission and mucosal healing[21,22].

Disease status ascertainment based on clinical and endoscopic outcomes is inadequate. To date, despite the availability of adequate evidence, the utility of histological healing remains limited[21,22]. Emerging evidence supports the impact of attaining simultaneous clinical, endoscopic and histological remission on disease outcomes. Herein, we discuss the emerging concept of disease clearance (DC) and the currently available evidence with a view to expanding its applicability in prospective high-profile research and its transition to clinical utility.

**TREAT TO TARGET: CURRENT GUIDELINES**

DC incorporates components of target indices proposed in the selecting therapeutic targets in inflammatory bowel disease (STRIDE) program guidelines[21,22]. To better grasp the reasoning for DC, it is imperative to review current therapeutic target recommendations for UC. In 2015, the STRIDE committee added a new dimension to treatment aspirations with the introduction of treat-to-target (T2T) therapy[21]. Prior to the T2T concept, the primary aim of therapy was to achieve steroid-free disease remission based on the absence or presence of clinical symptoms[21]. However, this approach fails to alter disease progression or prevent long-term disease sequalae[21,23,24]. In recent decades, promising data have supported the use of more objective endpoints in clinical practice and trials. Achieving endoscopic remission or mucosal healing was associated with improved long-term outcomes, such as steroid-free clinical remission; lower steroid utilization; and reduced rates of colectomy, dysplasia, CRC, disease relapse and hospitalization[21,25-30]. This finding supported the paradigm shift of treating beyond symptoms with a view to preventing structural damage and disability[21]. Furthermore, evidence of the effectiveness of T2T in treating other conditions, such as rheumatoid arthritis, diabetes and hypertension, supports its use in treating IBD[21,31-33]. Therapeutic adjustments were proposed on the basis of the achievement of predefined treatment goals with the aim of attenuating disease pathophysiology[21,34]. Subsequently, the importance of endoscopic assessment was outlined in the STRIDE[21]. Thus, the T2T strategy recommends the incorporation of a composite measure to ascertain disease status based on clinical remission/patient-reported outcomes (PROs) and endoscopic remission[21]. Clinical remission was defined as the resolution of rectal bleeding (RB) and normalization of stool frequency (SF)[21]. Clinical symptoms must be monitored every 3 months[21]. After adequate symptomatic control was achieved, follow-up every 6 months was considered adequate[21]. Endoscopic remission was defined as a Mayo endoscopic subscore of 0 or 1[21]. Endoscopic assessments were warranted every 3-6 months after the initiation of therapy[21]. When endoscopic evaluation is limited, resolution of inflammation should be ruled out by cross-sectional imaging[21]. A lack of evidence prevents the incorporation of histologic targets[21]. Finally, inflammatory biomarkers such as C-reactive protein (CRP) and fecal calprotectin (FC) were identified as adjunctive measures of inflammation rather than treatment targets[21].

Accumulating evidence and advancements in diagnostic modalities led to updated STRIDE guidelines[22,35]. In 2021, the STRIDE 2 guidelines incorporated time-dependent objective treatment targets ranging from short-term, intermediate-term and long-term goals of care[22]. The short-term target ensures that patients achieve a symptomatic response[21]. Intermediate goals include symptomatic remission, normalization of CRP levels and a decrease in FC to an acceptable range[21]. Approximately 15%-30% of patients fail to achieve a CRP response[36]. Therefore, the use of FC is preferred in biomarker assessments of inflammation[36]. The long-term treatment goals were endoscopic healing, normalization of quality of life and lack of disability[21]. Owing to superior disease outcomes, the endoscopic healing criteria were more stringent, with a Mayo endoscopic subscore of 0[22,30]. The low cost, ease of collection and lack of data from randomized controlled trials (RCTs) have led to treatment optimization driven by inflammatory biomarkers (CRP and FC)[22,37,38]. Despite the availability of evidence supporting the strong association of histologic healing (HH) with endoscopic healing and as a predictor of long-term outcomes, HH was endorsed only as an adjunctive target[22].

**DC IN UC**

***What is DC?***

DC is a novel emerging concept that has been adapted from dermatology[39]. DC is a composite measure defined as deep and comprehensive remission[40]. It encompasses the simultaneous attainment of clinical, endoscopic and histologic remission[40]. As a composite outcome, it holds the potential to improve treatment efficacy by increasing event rates and assessing all factors impacting disease activity[40]. Utilization of DC in psoriasis patients has yielded significant improvements in quality of life and disease control[41,42]. While it may represent the ultimate therapeutic target for psoriasis, DC was achieved in only 35.3% of patients[42]. DC has also demonstrated use in aiding therapeutic positioning in biologic drug efficacy comparator trials[43]. To avoid confusion in patients, DC should not be used synonymously with the term “cure”.

***Why incorporate DC in UC?***

Current treatment goals devised by STRIDE committee utilize these endpoints individually at several predetermined targeted time points[21,22]. STRIDE 2 proposes focusing on the short to long term in a T2T manner[22]. Several discrepancies exist indicating that our current definition of disease remission is subpar. Despite achieving endoscopic healing, persistent RB and increased SF can be observed in 39% and 24%, respectively, of patients[44]. A subset of these persistent symptoms can be attributed to functional disorders, with irritable bowel syndrome being the most prevalent[45-48]. Chronic inflammation alters colonic physiology and anatomical integrity, resulting in abnormal colonic motility, a reduction in goblet cells, aberrant barrier function and sequalae of intestinal fibrosis[49-52]. The extent and location of these changes contribute to persistent PROs despite adequate disease control[44,53,54]. This increases therapeutic risks due to aggressive treatment strategies and unnecessary changes in therapy. On the other hand, there remains a risk of underlying endoscopic disease in 20%-50% of patients attaining symptomatic remission[44,55-57]. Therefore, the assessment of clinically asymptomatic patients must be supplemented by other objective measures of inflammation. Patients in clinical remission are less likely to seek medical attention, thus increasing their risk of developing sequalae related to unchecked smoldering inflammation[58]. Despite the use of modern therapeutics, 10%-30% of patients still require proctocolectomy for medically refractory disease[59,60]. The absolute risk of colectomy increases with each subsequent switch in therapy[60]. While response rates vary across drug classes, 30%-40% of patients fail to respond to initial therapy[61]. Patients primed with prior biologic exposure exhibit a stepwise reduction in response to subsequent therapies[61]. However, remission rates remain suboptimal, with 20%-30% of patients achieving disease remission in UC induction trials, indicating a perceived therapeutic ceiling[17,62-70].

The persistence of histologic activity despite endoscopic inactivity has been shown to increase the risk of disease progression, relapse and complications[71-73]. A discordance between histologic activity and quiescent macroscopic activity has been reported in > 30% of cases[74]. Compared with mucosal healing, histologic activity has shown superior performance as an independent predictor of clinical course[74-76]. Histologic inflammation has also been deemed an independent risk factor for the development of CRC[7]. A 3- to 5-fold increase in the risk for CRC has been observed in patients with persistent histological activity[72]. The severity of histologic inflammation correlates with progression to advanced neoplasia[72]. Reversal of histologic disease has been shown to reduce the risk for CRC[77]. Achieving composite histologic and endoscopic improvement and remission correlate with PRO and reduced disability[78,79]. Despite being achievable in 55% of patients and growing evidence, histologic remission has not been formally designated as a therapeutic target[21,22,75]. In the majority of RCTs and regulatory trials, histological outcomes have been positioned as an exploratory or additional endpoint rather than a mandatory endpoint. Furthermore, the availability of multiple validated histological scoring systems, uniform endoscopic disease distribution and excellent predictive ability of inflammatory biomarkers for HH will facilitate the application of DC as a therapeutic outcome in UC[80-82]. This has given rise to the concept of deeper disease control by incorporating histologic activity as a mandatory endpoint. The data here support the hypothesis of total deep remission when combined with clinical, endoscopic and histological outcomes.

***Consensus definitions of DC by the International Organization for the Study of IBD***

In 2023, the first ever standardized guidelines defining DC were published by the International Organization for the Study of Inflammatory Bowel Diseases (IOIBD)[40]. It is expected that these guidelines will help standardize its use. Acknowledgment of the prognostic importance of histologic outcomes led to its incorporation as an official therapeutic endpoint[40]. The definition finalized by the IOIBD includes clinical, histologic and endoscopic remission of disease[40]. This culminates in all major time-dependent objective measures proposed in STRIDE 2. The expert consensus further delved deep to closely define each desired therapeutic target in line with the best available evidence. Clinical remission was defined as the total absence of clinical symptoms with a partial Mayo score of 0[40]. A Mayo endoscopic score of 0 and a Nancy histologic score of 0 define endoscopic remission and histologic remission, respectively[40].

***Evidence supporting DC in UC as a therapeutic target***

In a multicenter retrospective study, D’Amico *et al*[83] evaluated the impact of DC on long-term outcomes in UC patients[83]. DC was defined as simultaneous clinical (partial Mayo score ≤ 2), endoscopic (Mayo endoscopic score 0) or histological remission (Nancy index 0)[83]. Adult UC patients with an endohistological evaluation within 16 wk postinduction and at least 12 months of follow-up were included. The median follow-up time was 24 months[83]. Of the 494 patients in the study, 109 (22%) achieved DC[83]. Patients who achieved DC had shorter disease durations (5 years *vs* 9 years, *P* < 0.001)[83]. Significantly lower rates of negative outcomes such as hospitalization (5.5% *vs* 23.1%, *P* < 0.001) and surgery (1.8% *vs* 10.9%, *P* = 0.003) were noted in patients who underwent DC[83]. When reanalyzed using more stringent criteria (Mayo endoscopic score 0, Nancy index 0, normal SF and absence of RB), 19.8% of the patients met the criteria for DC[83]. The rates of hospitalization (22.7% *vs* 5.1%, *P* = 0.003) and surgery (10.9% *vs* 1.0%, *P* = 0.012) were greater in patients without DC[83]. Taken together, attaining DC within 16 wk posttherapeutic induction significantly lowers health care expenditure, the risk of hospitalization and surgery (Figure 1). This underlines the importance of initiating early treatment. Furthermore, this finding indicates the need for developing more efficient drugs[84].

Andronic and Toader[85] conducted an analysis of 79 UC patients[85]. For the purposes of this study, DC was defined as clinical (partial Mayo score ≤ 2), endoscopic (endoscopic Mayo score ≤ 1) or histologic remission (nancy index 0)[85]. At the initial time points, patients were divided into two subgroups. Groups 1 and 2 were deemed to have DC (*n* = 35) and without DC (*n* = 44), respectively[85]. Patients in both groups were followed for 12 months. Patients who achieved DC (Group 1) did not experience disease complications or required surgery (0% *vs* 31.8%, *P* = 0.03, OR = 23.1)[85]. The rate of hospitalization was significantly lower in Group 1 than in Group 2 (8.57% *vs* 54.54%, *P* = 0.002, OR = 0.57, RR = 0.224)[85].

Nascimento *et al*[86] conducted a retrospective analysis of 56 patients with UC and DC at baseline[86]. DC was defined as clinical (partial Mayo score ≤ 2), endoscopic (endoscopic Mayo score ≤ 1) or histologic remission (chronic inactive/quiescent colitis)[86]. During the 3-year follow-up, none of the patients with DC required surgery, and only one was hospitalized[86]. The overall probability of maintaining remission was 76% at 3 years[86].

A natural question arises whether the achievement of such a stringent endpoint is possible. Kruis *et al*[87] conducted a post hoc analysis of 4 phase 3 clinical trials[87]. The data were pooled from 860 UC patients to determine the percentage of DCs induced by different doses of mesalazine[87]. Overall, 20% achieved DC, 13% received 1.5 g/day, 21.8% received 3 g/day and 18.9% received 4.5/day[87]. Furthermore, the rates of DC were consistent across disease activities in a dose-dependent manner[87]. According to a post hoc analysis of the VARSITY comparator trial, at week 52, DC was noted in a greater percentage of patients receiving vedolizumab than in those receiving adalimumab (29.2% *vs* 16.3%)[88]. The data here suggest that DC is an achievable target in clinical practice, for which the likelihood of reaching this stringent outcome is 20%-29%.

**FUTURE AVENUES AND UTILITY IN CLINICAL LANDSCAPE**

While still in its infancy, it is expected that the definition of DC will evolve to include ongoing or upcoming results[40]. Emerging evidence supports the correlation of rectal muscle remodeling (rectal compliance) with histologic normalization and impact on quality of life[89]. Newer measures of quality of life, such as fecal urgency, are also under investigation[40]. Future avenues must assess superiority with differences in long-term outcomes with DC *vs* histological remission alone. Currently, the ongoing VERDICT trial aims to determine whether DC alone is superior to steroid-free symptomatic remission or steroid-free endoscopic remission combined with clinical remission[90]. To aid in the transition to routine clinical care, DC should be considered a secondary endpoint in RCTs[40]. Current evidence of DC is mainly driven by retrospective and post hoc analyses. Most current studies were conducted prior to the release of standardized DC guidelines. Therefore, some studies utilize different definitions of clinical remission. To accurately assess the impact of achieving DC on long-term outcomes, future studies must incorporate a uniform definition of DC. In addition, additional prospective studies with predefined objectives must be conducted. While patients who achieved DC were shown to have a lower baseline inflammatory burden, future studies must assess the role of inflammatory biomarkers. Given that achieving DC might be considered a difficult task, developing predictors of DC is important. The likelihood of achieving DC may be increased by dual therapy and by discovering biomarkers of drug response. Evidence pertaining to the value of dual therapy remains limited, with few prospective large-scale studies conducted to date[91]. Therefore, the role of dual therapy in inducing DC remains unknown. The impact of DC on dire sequalae such as dysplasia and CRC must also be ascertained. Transcriptional signatures specific to disease remission have also been delineated[40]. These include increased expression of genes regulating o-glycosylation and GAP junction trafficking and decreased expression of toll-like receptors[40,92]. This paves the way for the addition of molecular remission as an endpoint in DC with a direction for developing reliable molecular predictors of disease outcomes.

**CONCLUSION**

DC is a novel therapeutic outcome in UC patients and has the potential to provide superior disease control and reduce the risk of long-term complications. Prospective studies are necessary to ascertain the cost effectiveness, risk-benefit ratio and impact on long-term outcomes.

**REFERENCES**

1 **Kirsner JB**. Historical origins of current IBD concepts. *World J Gastroenterol* 2001; **7**: 175-184 [PMID: 11819757 DOI: 10.3748/wjg.v7.i2.175]

2 **Feuerstein JD**, Cheifetz AS. Ulcerative colitis: epidemiology, diagnosis, and management. *Mayo Clin Proc* 2014; **89**: 1553-1563 [PMID: 25199861 DOI: 10.1016/j.mayocp.2014.07.002]

3 **Abraham C**, Cho JH. Inflammatory bowel disease. *N Engl J Med* 2009; **361**: 2066-2078 [PMID: 19923578 DOI: 10.1056/NEJMra0804647]

4 **Hibi T**, Ogata H. Novel pathophysiological concepts of inflammatory bowel disease. *J Gastroenterol* 2006; **41**: 10-16 [PMID: 16501852 DOI: 10.1007/s00535-005-1744-3]

5 **Le Berre C**, Honap S, Peyrin-Biroulet L. Ulcerative colitis. *Lancet* 2023; **402**: 571-584 [PMID: 37573077 DOI: 10.1016/S0140-6736(23)00966-2]

6 **Lewis JD**, Parlett LE, Jonsson Funk ML, Brensinger C, Pate V, Wu Q, Dawwas GK, Weiss A, Constant BD, McCauley M, Haynes K, Yang JY, Schaubel DE, Hurtado-Lorenzo A, Kappelman MD. Incidence, Prevalence, and Racial and Ethnic Distribution of Inflammatory Bowel Disease in the United States. *Gastroenterology* 2023; **165**: 1197-1205.e2 [PMID: 37481117 DOI: 10.1053/j.gastro.2023.07.003]

7 **Colman RJ**, Rubin DT. Histological inflammation increases the risk of colorectal neoplasia in ulcerative colitis: a systematic review. *Intest Res* 2016; **14**: 202-210 [PMID: 27433141 DOI: 10.5217/ir.2016.14.3.202]

8 **Cohen RD**, Yu AP, Wu EQ, Xie J, Mulani PM, Chao J. Systematic review: the costs of ulcerative colitis in Western countries. *Aliment Pharmacol Ther* 2010; **31**: 693-707 [PMID: 20064142 DOI: 10.1111/j.1365-2036.2010.04234.x]

9 **Mehta F**. Report: economic implications of inflammatory bowel disease and its management. *Am J Manag Care* 2016; **22**: s51-s60 [PMID: 27269903]

10 **Krugliak Cleveland N**, Torres J, Rubin DT. What Does Disease Progression Look Like in Ulcerative Colitis, and How Might It Be Prevented? *Gastroenterology* 2022; **162**: 1396-1408 [PMID: 35101421 DOI: 10.1053/j.gastro.2022.01.023]

11 **Roda G**, Narula N, Pinotti R, Skamnelos A, Katsanos KH, Ungaro R, Burisch J, Torres J, Colombel JF. Systematic review with meta-analysis: proximal disease extension in limited ulcerative colitis. *Aliment Pharmacol Ther* 2017; **45**: 1481-1492 [PMID: 28449361 DOI: 10.1111/apt.14063]

12 **Fumery M**, Singh S, Dulai PS, Gower-Rousseau C, Peyrin-Biroulet L, Sandborn WJ. Natural History of Adult Ulcerative Colitis in Population-based Cohorts: A Systematic Review. *Clin Gastroenterol Hepatol* 2018; **16**: 343-356.e3 [PMID: 28625817 DOI: 10.1016/j.cgh.2017.06.016]

13 **Torres J**, Billioud V, Sachar DB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis as a progressive disease: the forgotten evidence. *Inflamm Bowel Dis* 2012; **18**: 1356-1363 [PMID: 22162423 DOI: 10.1002/ibd.22839]

14 **Rogler G**. Chronic ulcerative colitis and colorectal cancer. *Cancer Lett* 2014; **345**: 235-241 [PMID: 23941831 DOI: 10.1016/j.canlet.2013.07.032]

15 **de Campos Silva EF**, Baima JP, de Barros JR, Tanni SE, Schreck T, Saad-Hossne R, Sassaki LY. Risk factors for ulcerative colitis-associated colorectal cancer: A retrospective cohort study. *Medicine (Baltimore)* 2020; **99**: e21686 [PMID: 32769938 DOI: 10.1097/MD.0000000000021686]

16 **Sharma TT**, Rabizadeh RR, Prabhakar VS, Bury MI, Sharma AK. Evolving Experimental Platforms to Evaluate Ulcerative Colitis. *Adv Biol (Weinh)* 2022; **6**: e2200018 [PMID: 35866469 DOI: 10.1002/adbi.202200018]

17 **Rutgeerts P**, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF. Infliximab for induction and maintenance therapy for ulcerative colitis. *N Engl J Med* 2005; **353**: 2462-2476 [PMID: 16339095 DOI: 10.1056/NEJMoa050516]

18 **D'Haens GR**, van Deventer S. 25 years of anti-TNF treatment for inflammatory bowel disease: lessons from the past and a look to the future. *Gut* 2021; **70**: 1396-1405 [PMID: 33431575 DOI: 10.1136/gutjnl-2019-320022]

19 **Vieujean S**, D'Amico F, Netter P, Danese S, Peyrin-Biroulet L. Landscape of new drugs and targets in inflammatory bowel disease. *United European Gastroenterol J* 2022; **10**: 1129-1166 [PMID: 36112543 DOI: 10.1002/ueg2.12305]

20 **Mysler E**, Burmester GR, Saffore CD, Liu J, Wegrzyn L, Yang C, Betts KA, Wang Y, Irvine AD, Panaccione R. Safety of Upadacitinib in Immune-Mediated Inflammatory Diseases: Systematic Literature Review of Indirect and Direct Treatment Comparisons of Randomized Controlled Trials. *Adv Ther* 2024; **41**: 567-597 [PMID: 38169057 DOI: 10.1007/s12325-023-02732-6]

21 **Peyrin-Biroulet L**, Sandborn W, Sands BE, Reinisch W, Bemelman W, Bryant RV, D'Haens G, Dotan I, Dubinsky M, Feagan B, Fiorino G, Gearry R, Krishnareddy S, Lakatos PL, Loftus EV Jr, Marteau P, Munkholm P, Murdoch TB, Ordás I, Panaccione R, Riddell RH, Ruel J, Rubin DT, Samaan M, Siegel CA, Silverberg MS, Stoker J, Schreiber S, Travis S, Van Assche G, Danese S, Panes J, Bouguen G, O'Donnell S, Pariente B, Winer S, Hanauer S, Colombel JF. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. *Am J Gastroenterol* 2015; **110**: 1324-1338 [PMID: 26303131 DOI: 10.1038/ajg.2015.233]

22 **Turner D**, Ricciuto A, Lewis A, D'Amico F, Dhaliwal J, Griffiths AM, Bettenworth D, Sandborn WJ, Sands BE, Reinisch W, Schölmerich J, Bemelman W, Danese S, Mary JY, Rubin D, Colombel JF, Peyrin-Biroulet L, Dotan I, Abreu MT, Dignass A; International Organization for the Study of IBD. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. *Gastroenterology* 2021; **160**: 1570-1583 [PMID: 33359090 DOI: 10.1053/j.gastro.2020.12.031]

23 **Bouguen G**, Peyrin-Biroulet L. Surgery for adult Crohn's disease: what is the actual risk? *Gut* 2011; **60**: 1178-1181 [PMID: 21610273 DOI: 10.1136/gut.2010.234617]

24 **Magro F**, Rodrigues A, Vieira AI, Portela F, Cremers I, Cotter J, Correia L, Duarte MA, Tavares ML, Lago P, Ministro P, Peixe P, Lopes S, Garcia EB. Review of the disease course among adult ulcerative colitis population-based longitudinal cohorts. *Inflamm Bowel Dis* 2012; **18**: 573-583 [PMID: 21793126 DOI: 10.1002/ibd.21815]

25 **Ardizzone S**, Cassinotti A, Duca P, Mazzali C, Penati C, Manes G, Marmo R, Massari A, Molteni P, Maconi G, Porro GB. Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. *Clin Gastroenterol Hepatol* 2011; **9**: 483-489.e3 [PMID: 21195796 DOI: 10.1016/j.cgh.2010.12.028]

26 **Shah SC**, Colombel JF, Sands BE, Narula N. Mucosal Healing Is Associated With Improved Long-term Outcomes of Patients With Ulcerative Colitis: A Systematic Review and Meta-analysis. *Clin Gastroenterol Hepatol* 2016; **14**: 1245-1255.e8 [PMID: 26829025 DOI: 10.1016/j.cgh.2016.01.015]

27 **Sandborn WJ**, Hanauer S, Van Assche G, Panés J, Wilson S, Petersson J, Panaccione R. Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseases. *J Crohns Colitis* 2014; **8**: 927-935 [PMID: 24713173 DOI: 10.1016/j.crohns.2014.02.021]

28 **Ikeya K**, Hanai H, Sugimoto K, Osawa S, Kawasaki S, Iida T, Maruyama Y, Watanabe F. The Ulcerative Colitis Endoscopic Index of Severity More Accurately Reflects Clinical Outcomes and Long-term Prognosis than the Mayo Endoscopic Score. *J Crohns Colitis* 2016; **10**: 286-295 [PMID: 26581895 DOI: 10.1093/ecco-jcc/jjv210]

29 **Dulai PS**, Levesque BG, Feagan BG, D'Haens G, Sandborn WJ. Assessment of mucosal healing in inflammatory bowel disease: review. *Gastrointest Endosc* 2015; **82**: 246-255 [PMID: 26005012 DOI: 10.1016/j.gie.2015.03.1974]

30 **Colombel JF**, Rutgeerts P, Reinisch W, Esser D, Wang Y, Lang Y, Marano CW, Strauss R, Oddens BJ, Feagan BG, Hanauer SB, Lichtenstein GR, Present D, Sands BE, Sandborn WJ. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. *Gastroenterology* 2011; **141**: 1194-1201 [PMID: 21723220 DOI: 10.1053/j.gastro.2011.06.054]

31 **Smolen JS**, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, Combe B, Cutolo M, de Wit M, Dougados M, Emery P, Gibofsky A, Gomez-Reino JJ, Haraoui B, Kalden J, Keystone EC, Kvien TK, McInnes I, Martin-Mola E, Montecucco C, Schoels M, van der Heijde D; T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force. *Ann Rheum Dis* 2010; **69**: 631-637 [PMID: 20215140 DOI: 10.1136/ard.2009.123919]

32 **Wangnoo SK**, Sethi B, Sahay RK, John M, Ghosal S, Sharma SK. Treat-to-target trials in diabetes. *Indian J Endocrinol Metab* 2014; **18**: 166-174 [PMID: 24741511 DOI: 10.4103/2230-8210.129106]

33 **Atar D**, Birkeland KI, Uhlig T. 'Treat to target': moving targets from hypertension, hyperlipidaemia and diabetes to rheumatoid arthritis. *Ann Rheum Dis* 2010; **69**: 629-630 [PMID: 20237122 DOI: 10.1136/ard.2010.128462]

34 **Colombel JF**, Narula N, Peyrin-Biroulet L. Management Strategies to Improve Outcomes of Patients With Inflammatory Bowel Diseases. *Gastroenterology* 2017; **152**: 351-361.e5 [PMID: 27720840 DOI: 10.1053/j.gastro.2016.09.046]

35 **Pouillon L**, Peyrin-Biroulet L. It is Time to Revise the STRIDE Guidelines Determining Therapeutic Goals for Treat-to-Target in Inflammatory Bowel Disease. *J Crohns Colitis* 2018; **12**: 509 [PMID: 29309565 DOI: 10.1093/ecco-jcc/jjx174]

36 **Mosli MH**, Zou G, Garg SK, Feagan SG, MacDonald JK, Chande N, Sandborn WJ, Feagan BG. C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis. *Am J Gastroenterol* 2015; **110**: 802-19; quiz 820 [PMID: 25964225 DOI: 10.1038/ajg.2015.120]

37 **Osterman MT**, Aberra FN, Cross R, Liakos S, McCabe R, Shafran I, Wolf D, Hardi R, Nessel L, Brensinger C, Gilroy E, Lewis JD; DEAR Investigators. Mesalamine dose escalation reduces fecal calprotectin in patients with quiescent ulcerative colitis. *Clin Gastroenterol Hepatol* 2014; **12**: 1887-93.e3 [PMID: 24793028 DOI: 10.1016/j.cgh.2014.03.035]

38 **Lasson A**, Öhman L, Stotzer PO, Isaksson S, Überbacher O, Ung KA, Strid H. Pharmacological intervention based on fecal calprotectin levels in patients with ulcerative colitis at high risk of a relapse: A prospective, randomized, controlled study. *United European Gastroenterol J* 2015; **3**: 72-79 [PMID: 25653861 DOI: 10.1177/2050640614560785]

39 **Strober BE**, van der Walt JM, Armstrong AW, Bourcier M, Carvalho AVE, Chouela E, Cohen AD, de la Cruz C, Ellis CN, Finlay AY, Gottlieb AB, Gudjonsson JE, Iversen L, Kleyn CE, Leonardi CL, Lynde CW, Ryan C, Theng CT, Valenzuela F, Vender R, Wu JJ, Young HS, Kimball AB. Clinical Goals and Barriers to Effective Psoriasis Care. *Dermatol Ther (Heidelb)* 2019; **9**: 5-18 [PMID: 30578464 DOI: 10.1007/s13555-018-0279-5]

40 **D'Amico F**, Magro F, Siegmund B, Kobayashi T, Kotze PG, Solitano V, Caron B, Al Awadhi S, Hart A, Jairath V, Dignass A, Peyrin-Biroulet L, Danese S. Disease Clearance as a New Outcome in Ulcerative Colitis: a Systematic Review and Expert Consensus. *Inflamm Bowel Dis* 2023 [PMID: 37549104 DOI: 10.1093/ibd/izad159]

41 **Elewski BE**, Puig L, Mordin M, Gilloteau I, Sherif B, Fox T, Gnanasakthy A, Papavassilis C, Strober BE. Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75-89 response: results from two phase 3 studies of secukinumab. *J Dermatolog Treat* 2017; **28**: 492-499 [PMID: 28266243 DOI: 10.1080/09546634.2017.1294727]

42 **Shelton SK**, Bai SR, Jordan JK, Sheehan AH. Ixekizumab: A Review of Its Use for the Management of Moderate to Severe Plaque Psoriasis. *Ann Pharmacother* 2019; **53**: 276-284 [PMID: 30187769 DOI: 10.1177/1060028018799982]

43 **Reich K**, Gooderham M, Thaçi D, Crowley JJ, Ryan C, Krueger JG, Tsai TF, Flack M, Gu Y, Williams DA, Thompson EHZ, Paul C. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. *Lancet* 2019; **394**: 576-586 [PMID: 31280967 DOI: 10.1016/S0140-6736(19)30952-3]

44 **Colombel JF**, Keir ME, Scherl A, Zhao R, de Hertogh G, Faubion WA, Lu TT. Discrepancies between patient-reported outcomes, and endoscopic and histological appearance in UC. *Gut* 2017; **66**: 2063-2068 [PMID: 27590995 DOI: 10.1136/gutjnl-2016-312307]

45 **Szałwińska P**, Włodarczyk J, Spinelli A, Fichna J, Włodarczyk M. IBS-Symptoms in IBD Patients-Manifestation of Concomitant or Different Entities. *J Clin Med* 2020; **10** [PMID: 33374388 DOI: 10.3390/jcm10010031]

46 **Hoekman DR**, Zeevenhooven J, D'Haens GR, Benninga MA. The prevalence of irritable bowel syndrome-type symptoms in inflammatory bowel disease patients in remission. *Eur J Gastroenterol Hepatol* 2017; **29**: 1086-1090 [PMID: 28639969 DOI: 10.1097/MEG.0000000000000921]

47 **Halpin SJ**, Ford AC. Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: systematic review and meta-analysis. *Am J Gastroenterol* 2012; **107**: 1474-1482 [PMID: 22929759 DOI: 10.1038/ajg.2012.260]

48 **Fairbrass KM**, Costantino SJ, Gracie DJ, Ford AC. Prevalence of irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease in remission: a systematic review and meta-analysis. *Lancet Gastroenterol Hepatol* 2020; **5**: 1053-1062 [PMID: 33010814 DOI: 10.1016/S2468-1253(20)30300-9]

49 **Singh V**, Johnson K, Yin J, Lee S, Lin R, Yu H, In J, Foulke-Abel J, Zachos NC, Donowitz M, Rong Y. Chronic Inflammation in Ulcerative Colitis Causes Long-Term Changes in Goblet Cell Function. *Cell Mol Gastroenterol Hepatol* 2022; **13**: 219-232 [PMID: 34418586 DOI: 10.1016/j.jcmgh.2021.08.010]

50 **Bassotti G**, Antonelli E, Villanacci V, Baldoni M, Dore MP. Colonic motility in ulcerative colitis. *United European Gastroenterol J* 2014; **2**: 457-462 [PMID: 25452840 DOI: 10.1177/2050640614548096]

51 **Park JM**, Kim J, Lee YJ, Bae SU, Lee HW. Inflammatory bowel disease-associated intestinal fibrosis. *J Pathol Transl Med* 2023; **57**: 60-66 [PMID: 36623814 DOI: 10.4132/jptm.2022.11.02]

52 **Antoni L**, Nuding S, Wehkamp J, Stange EF. Intestinal barrier in inflammatory bowel disease. *World J Gastroenterol* 2014; **20**: 1165-1179 [PMID: 24574793 DOI: 10.3748/wjg.v20.i5.1165]

53 **Jharap B**, Sandborn WJ, Reinisch W, D'Haens G, Robinson AM, Wang W, Huang B, Lazar A, Thakkar RB, Colombel JF. Randomised clinical study: discrepancies between patient-reported outcomes and endoscopic appearance in moderate to severe ulcerative colitis. *Aliment Pharmacol Ther* 2015; **42**: 1082-1092 [PMID: 26381802 DOI: 10.1111/apt.13387]

54 **Ordille AJ**, Phadtare S. Intensity-specific considerations for exercise for patients with inflammatory bowel disease. *Gastroenterol Rep (Oxf)* 2023; **11**: goad004 [PMID: 36814502 DOI: 10.1093/gastro/goad004]

55 **Coates MD**, Soriano C, Dalessio S, Stuart A, Walter V, Koltun W, Bernasko N, Tinsley A, Clarke K, Williams ED. Gastrointestinal hypoalgesia in inflammatory bowel disease. *Ann Gastroenterol* 2020; **33**: 45-52 [PMID: 31892797 DOI: 10.20524/aog.2019.0442]

56 **Sakata T**, Niwa Y, Goto H, Hirooka Y, Hayakawa T, Ohmiya N, Kobayashi S. Asymptomatic inflammatory bowel disease with special reference to ulcerative colitis in apparently healthy persons. *Am J Gastroenterol* 2001; **96**: 735-739 [PMID: 11280543 DOI: 10.1111/j.1572-0241.2001.03614.x]

57 **Baars JE**, Nuij VJ, Oldenburg B, Kuipers EJ, van der Woude CJ. Majority of patients with inflammatory bowel disease in clinical remission have mucosal inflammation. *Inflamm Bowel Dis* 2012; **18**: 1634-1640 [PMID: 22069022 DOI: 10.1002/ibd.21925]

58 **Coates MD**, Binion DG. Silent Inflammatory Bowel Disease. *Crohns Colitis 360* 2021; **3**: otab059 [PMID: 34805984 DOI: 10.1093/crocol/otab059]

59 **Wetwittayakhlang P**, Gonczi L, Lakatos L, Kurti Z, Golovics P, Pandur T, David G, Erdelyi Z, Szita I, Lakatos PL. Long-term Colectomy Rates of Ulcerative Colitis over 40 Years of Different Therapeutic Eras-Results from a Western Hungarian Population-based Inception Cohort Between 1977 and 2020. *J Crohns Colitis* 2023; **17**: 712-721 [PMID: 36539328 DOI: 10.1093/ecco-jcc/jjac188]

60 **Barnes EL**, Zhang X, Long MD, Herfarth HH, Kappelman MD. Rate of Colectomy Increases Within 12 Months of Sequential Therapy for Ulcerative Colitis. *Am J Gastroenterol* 2023; **118**: 2080-2083 [PMID: 37216596 DOI: 10.14309/ajg.0000000000002331]

61 **Singh S**, George J, Boland BS, Vande Casteele N, Sandborn WJ. Primary Non-Response to Tumor Necrosis Factor Antagonists is Associated with Inferior Response to Second-line Biologics in Patients with Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis. *J Crohns Colitis* 2018; **12**: 635-643 [PMID: 29370397 DOI: 10.1093/ecco-jcc/jjy004]

62 **Sandborn WJ**, van Assche G, Reinisch W, Colombel JF, D'Haens G, Wolf DC, Kron M, Tighe MB, Lazar A, Thakkar RB. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. *Gastroenterology* 2012; **142**: 257-65.e1-3 [PMID: 22062358 DOI: 10.1053/j.gastro.2011.10.032]

63 **Sandborn WJ**, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, Adedokun OJ, Guzzo C, Colombel JF, Reinisch W, Gibson PR, Collins J, Järnerot G, Hibi T, Rutgeerts P; PURSUIT-SC Study Group. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. *Gastroenterology* 2014; **146**: 85-95; quiz e14-5 [PMID: 23735746 DOI: 10.1053/j.gastro.2013.05.048]

64 **Feagan BG**, Rubin DT, Danese S, Vermeire S, Abhyankar B, Sankoh S, James A, Smyth M. Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists. *Clin Gastroenterol Hepatol* 2017; **15**: 229-239.e5 [PMID: 27639327 DOI: 10.1016/j.cgh.2016.08.044]

65 **Peyrin-Biroulet L**, Hart A, Bossuyt P, Long M, Allez M, Juillerat P, Armuzzi A, Loftus EV Jr, Ostad-Saffari E, Scalori A, Oh YS, Tole S, Chai A, Pulley J, Lacey S, Sandborn WJ; HICKORY Study Group. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial. *Lancet Gastroenterol Hepatol* 2022; **7**: 128-140 [PMID: 34798039 DOI: 10.1016/S2468-1253(21)00298-3]

66 **Sands BE**, Sandborn WJ, Panaccione R, O'Brien CD, Zhang H, Johanns J, Adedokun OJ, Li K, Peyrin-Biroulet L, Van Assche G, Danese S, Targan S, Abreu MT, Hisamatsu T, Szapary P, Marano C; UNIFI Study Group. Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. *N Engl J Med* 2019; **381**: 1201-1214 [PMID: 31553833 DOI: 10.1056/NEJMoa1900750]

67 **Sandborn WJ**, Su C, Sands BE, D'Haens GR, Vermeire S, Schreiber S, Danese S, Feagan BG, Reinisch W, Niezychowski W, Friedman G, Lawendy N, Yu D, Woodworth D, Mukherjee A, Zhang H, Healey P, Panés J; OCTAVE Induction 1, OCTAVE Induction 2, and OCTAVE Sustain Investigators. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. *N Engl J Med* 2017; **376**: 1723-1736 [PMID: 28467869 DOI: 10.1056/NEJMoa1606910]

68 **Feagan BG**, Danese S, Loftus EV Jr, Vermeire S, Schreiber S, Ritter T, Fogel R, Mehta R, Nijhawan S, Kempiński R, Filip R, Hospodarskyy I, Seidler U, Seibold F, Beales ILP, Kim HJ, McNally J, Yun C, Zhao S, Liu X, Hsueh CH, Tasset C, Besuyen R, Watanabe M, Sandborn WJ, Rogler G, Hibi T, Peyrin-Biroulet L. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial. *Lancet* 2021; **397**: 2372-2384 [PMID: 34090625 DOI: 10.1016/S0140-6736(21)00666-8]

69 **Sandborn WJ**, Feagan BG, D'Haens G, Wolf DC, Jovanovic I, Hanauer SB, Ghosh S, Petersen A, Hua SY, Lee JH, Charles L, Chitkara D, Usiskin K, Colombel JF, Laine L, Danese S; True North Study Group. Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis. *N Engl J Med* 2021; **385**: 1280-1291 [PMID: 34587385 DOI: 10.1056/NEJMoa2033617]

70 **Danese S**, Vermeire S, Zhou W, Pangan AL, Siffledeen J, Greenbloom S, Hébuterne X, D'Haens G, Nakase H, Panés J, Higgins PDR, Juillerat P, Lindsay JO, Loftus EV Jr, Sandborn WJ, Reinisch W, Chen MH, Sanchez Gonzalez Y, Huang B, Xie W, Liu J, Weinreich MA, Panaccione R. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. *Lancet* 2022; **399**: 2113-2128 [PMID: 35644166 DOI: 10.1016/S0140-6736(22)00581-5]

71 **Ozaki R**, Kobayashi T, Okabayashi S, Nakano M, Morinaga S, Hara A, Ohbu M, Matsuoka K, Toyonaga T, Saito E, Hisamatsu T, Hibi T. Histological Risk Factors to Predict Clinical Relapse in Ulcerative Colitis With Endoscopically Normal Mucosa. *J Crohns Colitis* 2018; **12**: 1288-1294 [PMID: 29939231 DOI: 10.1093/ecco-jcc/jjy092]

72 **Gupta RB**, Harpaz N, Itzkowitz S, Hossain S, Matula S, Kornbluth A, Bodian C, Ullman T. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. *Gastroenterology* 2007; **133**: 1099-105; quiz 1340-1 [PMID: 17919486 DOI: 10.1053/j.gastro.2007.08.001]

73 **Peyrin-Biroulet L**, Bressenot A, Kampman W. Histologic remission: the ultimate therapeutic goal in ulcerative colitis? *Clin Gastroenterol Hepatol* 2014; **12**: 929-34.e2 [PMID: 23911875 DOI: 10.1016/j.cgh.2013.07.022]

74 **Bryant RV**, Winer S, Travis SP, Riddell RH. Systematic review: histological remission in inflammatory bowel disease. Is 'complete' remission the new treatment paradigm? An IOIBD initiative. *J Crohns Colitis* 2014; **8**: 1582-1597 [PMID: 25267173 DOI: 10.1016/j.crohns.2014.08.011]

75 **Rath T**, Atreya R, Neurath MF. Is histological healing a feasible endpoint in ulcerative colitis? *Expert Rev Gastroenterol Hepatol* 2021; **15**: 665-674 [PMID: 33481635 DOI: 10.1080/17474124.2021.1880892]

76 **Bryant RV**, Burger DC, Delo J, Walsh AJ, Thomas S, von Herbay A, Buchel OC, White L, Brain O, Keshav S, Warren BF, Travis SP. Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up. *Gut* 2016; **65**: 408-414 [PMID: 25986946 DOI: 10.1136/gutjnl-2015-309598]

77 **Korelitz BI**, Sultan K, Kothari M, Arapos L, Schneider J, Panagopoulos G. Histological healing favors lower risk of colon carcinoma in extensive ulcerative colitis. *World J Gastroenterol* 2014; **20**: 4980-4986 [PMID: 24803809 DOI: 10.3748/wjg.v20.i17.4980]

78 **Verstockt B**, Pouillon L, Ballaux F, Jorissen C, Hoefkens E, Lembrechts N, Bossuyt P. Patient-reported Outcomes and Disability Are Associated with Histological Disease Activity in Patients with Ulcerative Colitis: Results from the APOLLO Study. *J Crohns Colitis* 2023; **17**: 1046-1054 [PMID: 36708189 DOI: 10.1093/ecco-jcc/jjad015]

79 **Parkes G**, Ungaro RC, Danese S, Abreu MT, Arenson E, Zhou W, Ilo D, Laroux FS, Deng H, Sanchez Gonzalez Y, Peyrin-Biroulet L. Correlation of mucosal healing endpoints with long-term clinical and patient-reported outcomes in ulcerative colitis. *J Gastroenterol* 2023; **58**: 990-1002 [PMID: 37490069 DOI: 10.1007/s00535-023-02013-7]

80 **Kawashima K**, Oshima N, Kishimoto K, Kataoka M, Fukunaga M, Kotani S, Sonoyama H, Oka A, Mishima Y, Kazumori H, Ishikawa N, Araki A, Ishihara S. Low Fecal Calprotectin Predicts Histological Healing in Patients with Ulcerative Colitis with Endoscopic Remission and Leads to Prolonged Clinical Remission. *Inflamm Bowel Dis* 2023; **29**: 359-366 [PMID: 35583193 DOI: 10.1093/ibd/izac095]

81 **Cannatelli R**, Bazarova A, Zardo D, Nardone OM, Shivaji U, Smith SCL, Gkoutos G, Ricci C, Gui XS, Ghosh S, Iacucci M. Fecal Calprotectin Thresholds to Predict Endoscopic Remission Using Advanced Optical Enhancement Techniques and Histological Remission in IBD Patients. *Inflamm Bowel Dis* 2021; **27**: 647-654 [PMID: 32592477 DOI: 10.1093/ibd/izaa163]

82 **Yoon H**, Jangi S, Dulai PS, Boland BS, Prokop LJ, Jairath V, Feagan BG, Sandborn WJ, Singh S. Incremental Benefit of Achieving Endoscopic and Histologic Remission in Patients With Ulcerative Colitis: A Systematic Review and Meta-Analysis. *Gastroenterology* 2020; **159**: 1262-1275.e7 [PMID: 32585306 DOI: 10.1053/j.gastro.2020.06.043]

83 **D'Amico F**, Fiorino G, Solitano V, Massarini E, Guillo L, Allocca M, Furfaro F, Zilli A, Bonovas S, Magro F, Peyrin-Biroulet L, Danese S. Ulcerative colitis: Impact of early disease clearance on long-term outcomes - A multicenter cohort study. *United European Gastroenterol J* 2022; **10**: 775-782 [PMID: 36107109 DOI: 10.1002/ueg2.12288]

84 **Schoefs E**, Vermeire S, Ferrante M, Sabino J, Lambrechts T, Avedano L, Haaf I, De Rocchis MS, Broggi A, Sajak-Szczerba M, Saldaña R, Janssens R, Huys I. What are the Unmet Needs and Most Relevant Treatment Outcomes According to Patients with Inflammatory Bowel Disease? A Qualitative Patient Preference Study. *J Crohns Colitis* 2023; **17**: 379-388 [PMID: 36165579 DOI: 10.1093/ecco-jcc/jjac145]

85 **Andronic AM**, Toader E. P398 Disease clearance: a potential target for management of patients with Ulcerative Colitis. *J Crohn's Colitis* 2023; **17** Suppl 1: i529-i529 [DOI: 10.1093/ecco-jcc/jjac190.0528]

86 **Nascimento C**, Revés J, Roque Ramos L, Carolina P, Fidalgo C, Glória L, Torres J. P406 Disease clearance in patients with ulcerative colitis treated with aminosalicylates. *J Crohn's Colitis* 2022; **16** Suppl 1: i398-i398 [DOI: 10.1093/ecco-jcc/jjab232.533]

87 **Kruis W**, Meszaros S, Wehrum S, Mueller R, Greinwald R, Nacak T. Mesalazine granules promote disease clearance in patients with mild-to-moderate ulcerative colitis. *United European Gastroenterol J* 2023; **11**: 775-783 [PMID: 37490352 DOI: 10.1002/ueg2.12435]

88 **Danese S**, Schreiber S, Loftus E, Jr., Colombel JF, Peyrin-Biroulet L, Agboton C, Lindner D, Lirio R, Sands B. P271 Evolving Targets in Ulcerative colitis: Defining Disease Clearance in the VARSITY Study. *J Crohn's Colitis* 2021; **15** Suppl 1: S305-S305 [DOI: 10.1093/ecco-jcc/jjab076.396]

89 **Krugliak Cleveland N**, Rai V, El Jurdi K, Rao SS, Giurcanu MC, Rubin DT. Ulcerative Colitis Patients Have Reduced Rectal Compliance Compared With Non-Inflammatory Bowel Disease Controls. *Gastroenterology* 2022; **162**: 331-333.e1 [PMID: 34597674 DOI: 10.1053/j.gastro.2021.09.052]

90 **Jairath V**, Zou G, Wang Z, Adsul S, Colombel JF, D’Haens GR, Freire M, Moran GW, Peyrin-Biroulet L, Sandborn WJ, Sebastian S, Travis S, Vermeire S, Radulescu G, Sigler J, Mcfarlane S, Arya N, Beaton M, Bossuyt P, Green D, Harlan III W, Horynski M, Klopocka M, Petroniene R, Silverberg MS, Wolanski L, Feagan BG, Group obotVS. P588 Interim results from the randomised VERDICT trial to determine the optimal treatment target in patients with ulcerative colitis. *J Crohn's Colitis* 2023; **17** Suppl 1: i716-i717 [DOI: 10.1093/ecco-jcc/jjac190.0718]

91 **Berinstein EM**, Sheehan JL, Jacob J, Steiner CA, Stidham RW, Shannon C, Bishu S, Levine J, Cohen-Mekelburg SA, Waljee AK, Higgins PDR, Berinstein JA. Efficacy and Safety of Dual Targeted Therapy for Partially or Non-responsive Inflammatory Bowel Disease: A Systematic Review of the Literature. *Dig Dis Sci* 2023; **68**: 2604-2623 [PMID: 36807832 DOI: 10.1007/s10620-023-07837-0]

92 **Fenton CG**, Taman H, Florholmen J, Sørbye SW, Paulssen RH. Transcriptional Signatures That Define Ulcerative Colitis in Remission. *Inflamm Bowel Dis* 2021; **27**: 94-105 [PMID: 32322884 DOI: 10.1093/ibd/izaa075]

**Footnotes**

**Conflict-of-interest statement:** All authors of this manuscript do not have any conflict-of-interest to declare.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** January 6, 2024

**First decision:** February 6, 2024

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** United States

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B


Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Knudsen T, Denmark **S-Editor:** Fan JR **L-Editor:** A **P-Editor:**

**Figure Legends**



**Figure 1 Defining disease clearance in ulcerative colitis and its perceived impact on clinical outcomes.**